This study was performed to investigate incidence, causes and factors influencing mortality after haploidentical hematopoietic stem cell transplantation (HSCT) and to compare differences between haploidentical HSCT and HLA-identical sibling HSCT. From January 2000 to June 2011, 1411 patients with acute leukemia or myelodysplastic syndrome were included in this study. Of these patients, 571 received HLA-identical sibling HSCT and 840 received haploidentical HSCT. The cumulative incidence of overall mortality and transplant-related mortality (TRM) after haploidentical HSCT was higher than those after HLA-identical sibling HSCT (38.7% vs 33.3%, P = 0.012 and 27.5% vs 19.9%, P = 0.002), but the incidence of relapse-related mortality (RRM) did not differ between the two groups (15.6% vs 16.7%, P = 0.943). A multivariate analysis suggested that high-risk disease status and haploidentical HSCT correlated with a higher incidence of overall mortality (P o0.0001, hazard ratio = 1.911 and P = 0.019, hazard ratio = 1.249); in addition, in haploidentical HSCT, only high-risk disease status correlated with a higher incidence of overall mortality (P o0.0001, hazard ratio = 1.845). Our study suggested that haploidentical HSCT provided a higher incidence of overall mortality and TRM but the same incidence of RRM compared with HLA-identical sibling HSCT. Therefore, HLA-identical sibling HSCT remains the first choice, but haploidentical HSCT is available for patients without an HLA-identical sibling donor.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for a variety of hematological malignancies. Over the past few decades, many changes have been made to improve the outcome of transplants, including improvements in the conditioning regimen, prophylaxis and the treatment of organ toxicity, GvHD, infection and relapse post transplant. These advances have all resulted in a reduction of overall mortality post transplant. [1] [2] [3] Data from CIBMTR (Center for International Blood and Marrow Transplant Research) have indicated that the incidences of overall mortality post transplant are ∼ 20-30% in HLA-identical sibling HSCT and nearly 30-40% in unrelated HSCT. However, a lack of HLA-identical sibling donors or unrelated donors has restricted the application of allo-HSCT in hematological malignancies.
Haploidentical HSCT offers the benefits of rapid and nearly universal donor availability and, in the past decade, has been accepted worldwide as an alternative treatment for patients with hematological malignancies who do not have an HLA-identical sibling donor or who require urgent transplantation. [4] [5] [6] [7] [8] [9] [10] Recently, some advances in effective T-cell depletion and intensive immunosuppression induced by a conditioning regimen have significantly reduced the development of severe GvHD and graft failure after haploidentical HSCT. In addition, some changes in the prevention and treatment of infection and relapse have also improved the overall survival after haploidentical HSCT. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Moreover, our previous study suggested that in patients with acute leukemia, haploidentical HSCT provides a transplant-related mortality (TRM) and overall survival comparable to that found in HLA-identical sibling HSCT (TRM: 22% vs 14%, P = 0.10 and overall survival: 71% vs 72%, P = 0.72). 4 However, the incidence of overall mortality in haploidentical HSCT remains higher than 30%; therefore, the causes and factors that influence mortality after haploidentical HSCT needed to be investigated in detail to further reduce the incidence of overall mortality post transplant. Therefore, the incidence, causes and factors influencing mortality after haploidentical HSCT were investigated in this study, and the differences in the incidence and causes of mortality post transplant were compared between haploidentical HSCT and HLA-identical sibling HSCT.
conditioning regimen that included cytosine arabinoside (Ara-c, 2 g/m 2 / day, day − 9), busulfan (Bu, 3.2 mg/kg/day i.v., days − 8, − 7 and − 6), cyclophosphamide (Cy, 1.8 g/m 2 /day, days − 5 and − 4) and simustine (Me-CCNU, 250 mg/m 2 /day, day − 3), or a TBI-based conditioning regimen that included (TBI (770 cGy in single dose, day − 6), Cy (days − 5 and − 4) and Me-CCNU (day − 3). The haploidentical transplant patients received a Bu-based conditioning regimen that included Ara-c (4 g/m 2 /day, days − 10 and − 9), Bu (days − 8, − 7 and − 6), Cy (days − 5 and − 4), antihuman thymocyte immunoglobulin (ATG, 2.5 mg/kg/day, days − 5, − 4, − 3 and − 2) and Me-CCNU (day − 3), or a TBI-based conditioning regimen that included TBI (day − 6), Cy (days − 5 and − 4), ATG (days − 5, − 4, − 3 and − 2) and Me-CCNU (day − 3).
Stem cell source and harvesting Donor bone marrow (BM) cells and/or peripheral blood (PB) cells were collected using standard mobilization protocols. In all patients, G-CSF (5 μg/kg/day) was used to mobilize BM cells and PB cells. BM cells were harvested on day 01 (after 4 days of G-CSF), and PB cells were harvested on day 02 (after 5 days of G-CSF).
GvHD prophylaxis
All patients received cyclosporine A, mycophenolate mofetil and short-term methotrexate for the prophylaxis of GvHD. Cyclosporine A was administered at a dose of 2.5 mg/kg/day starting on day − 9 pretransplant and was then adjusted to maintain a plasma concentration of 150-250 ng/ml. Mycophenolate mofetil was administered orally at a dosage of 0.5 g every 12 h starting on day − 9 pretransplant. Subsequently, in patients receiving haploidentical HSCT, mycophenolate mofetil was tapered to 0.25 g every 12 h on day 30 and was discontinued on day 60 post transplant; however, in patients receiving HLA-identical sibling HSCT, mycophenolate mofetil was discontinued immediately on day 30 post transplant. Moreover, in patients receiving haploidentical HSCT, methotrexate was administered intravenously at dosages of 15 mg/m 2 on day 1 and 10 mg/m 2 on days 3, 6 and 11 post transplant; however, in patients receiving HLA-identical sibling HSCT, methotrexate was administered intravenously at dosages of 15 mg/m 2 on day 1 and 10 mg/m 2 on days 3 and 5 post transplant.
Protocol for modified DLI
The procedure for modified donor lymphocyte infusion (DLI) consisted of the infusions of G-CSF-mobilized PBSCs and the application of immunosuppressive agents after infusions to prevent DLI-associated GvHD. If refractory/relapsed acute leukemia was diagnosed pretransplant, prophylactic modified DLI was administered as described previously. 11 If minimal residual disease-positive status occurred post transplant, risk stratificationdirected modified DLI was administered as described in a previously published article. 12 If relapse occurred post transplant, therapeutic modified DLI was administered as described in a previously published article. 13 Definitions and evaluation High-risk disease status was defined as refractory/relapsed acute leukemia that included acute leukemia in a nonremission state, untreated acute leukemia or relapsed acute leukemia. GvHD was scored as acute or chronic based on published criteria.
14 Relapse was defined as BM, extramedullary or both based on common morphological criteria.
The cause of mortality was first categorized into relapse-related mortality (RRM) and TRM. The patients who never achieved remission or died with relapse at any time post transplant were classified as RRM. The patients who died without relapse were classified as TRM. Subsequently, patients who died of TRM were further subdivided into GvHD-related mortality, infection-related mortality or other causes-related mortality according to the records of the primary cause of mortality. Patients who had both infectious disease and GvHD were classified according to the main and direct causes of mortality. The patients who died of TRM without any record of the primary causes of mortality were included in the other causes-related mortality group.
Statistical analyses
All statistical analyses were performed using SPSS version 13.0 (Chicago, IL, USA) with the exception of the cumulative incidence analyses that were performed using the R software (Murray Hill, NJ, USA). The incidences of mortality were plotted using the Kaplan-Meier method and compared using the log-rank test. The cumulative incidences of relapse and TRM were calculated by accounting for competing risks. Univariate analyses were performed using the χ 2 test for categorical variables and the MannWhitney test for continuous variables. Multivariate analyses were performed using the Cox proportional hazards model. The end point of follow-up for all surviving subjects was 31 December 2013. Unless otherwise specified, all P-values are two sided, and a P-value of o0.05 was considered significant.
RESULTS

Patient characteristics
From 2000 to 2011, a total of 2059 consecutive patients received myeloablative allo-HSCT in our center due to leukemia or MDS. Of these 2059 patients, 177 who received unrelated HSCT and another 471 who had CML were excluded from this study. Finally, 1411 patients were included in this study, with a median age of 30 years (range: 2-67 years) and a median follow-up of 41.90 months (range: 12.23-150.77 months) for the surviving patients (Table 1) . Of these 1411 patients, 571 received HLA-identical sibling HSCT, and the other 840 received haploidentical HSCT. Of the patients receiving haploidentical HSCT, more patients had ALL (46.3% vs 33.3%, P o0.001) and fewer patients had AML or MDS (46.7% vs 55.9%, P o 0.001; 7.0 vs 10.9%, P o 0.0001) than in patients receiving HLA-identical sibling HSCT. Moreover, the patients receiving haploidentical HSCT were younger than the patients receiving HLA-identical sibling HSCT (25.0% vs 38.0, Po 0.0001; Table 1 ).
Allo-HSCT from haploidentical donors
Of the 840 patients receiving haploidentical HSCT, 305 (36.2%) died post transplant. As expected, only 9 patients (3.0%) died within the first month post transplant, and only 14 patients (4.6%) died 2 years after transplant. The cumulative incidence of overall mortality after haploidentical HSCT was 1.1% at 1 month, 6.9% at 3 months, 16.2% at 6 months, 25.2% at 1 year, 35.6% at 2 years, 37.4% at 3 years, 38.7% at 5 years and 38.7% at 10 years ( Figure 1a) . Of the 305 patients who died post transplant, 151 died of infection (49.5%), 98 died of relapse (32.2%), 19 died of GvHD (6.2%) and 37 died of other causes (12.1%). The cumulative incidences of TRM and RRM at 10 years were 27.5% and 15.6%, respectively. In addition, the incidences of TRM and RRM differed by post-transplant time point (Figures 1b-d ).
Allo-HSCT from HLA-identical sibling donors Of the 571 patients receiving HLA-identical sibling HSCT, 176 (30.8%) died post transplant. As expected, only 4 patients (2.3%) died within the first month after transplant, and 20 patients (11.4%) had died 2 years after the transplant. The cumulative incidence of overall mortality after HLA-identical sibling HSCT was 0.7% at 1 month, 5.4% at 3 months, 13.0% at 6 months, 21.2% at 1 year, 27.2% at 2 years, 30.8% at 3 years, 32.3% at 5 years and 33.3% at 10 years (Figure 1a) . Of the 176 patients who died post transplant, 73 (41.5%) died of relapse, 69 died of infection (39.2%), 11 died of GvHD (6.3%) and 23 died of other causes (13.1%). The cumulative incidences of TRM and RRM at 10 years were 19.9% and 16.7%, respectively. In addition, the incidence of TRM and RRM varied by post-transplant time point (Figures 1b-d) .
Comparison between HLA-identical sibling HSCT and haploidentical HSCT The incidences of overall mortality and TRM were significantly higher in patients receiving haploidentical HSCT than in patients receiving HLA-identical sibling HSCT (P = 0.012 and P = 0.002). However, the incidence of RRM did not significantly differ between the two groups (P = 0.943; Table 2 and Figures 1a-c) . Furthermore, the incidence of overall mortality (36.3% vs 30.8%, P = 0.082) or RRM (14.6% vs 15.8%, P = 0.724) did not significantly differ in the patients with AML, but the incidence of TRM tended to be higher in patients receiving haploidentical HSCT than in patients receiving HLA-identical sibling HSCT (25.5% vs 17.8%, P = 0.054; Figures 2a-c) . Furthermore, the incidences of overall mortality (39.9% vs 39.3%, P = 0.786), TRM (27.8% vs 23.4%, P = 0.261) or RRM (17.2% vs 20.7%, P = 0.355) in patients with ALL did not significantly differ between the two groups (Figures 2d-f) . However, the incidences of overall mortality and TRM in patients with MDS were significantly higher in patients receiving haploidentical HSCT than in patients receiving HLA-identical sibling HSCT (45.9% vs 29.8%, P = 0.005 and 39.7% vs 21.4%, P = 0.001, respectively), but the incidence of RRM did not significantly differ between the two groups (10.3% vs 10.7%, P = 0.721; Figures 2g-i) . Moreover, the incidence of infectionrelated mortality was significantly higher in patients receiving haploidentical HSCT than in the patients receiving HLA-identical sibling HSCT (21.2% vs 13.4%, P = 0.002), but the incidence of GvHD-related mortality did not significantly differ between the two groups (3.3% vs 3.0%, P = 0.469; Table 2 ).
Factors that influenced the incidence of mortality after allo-HSCT Based on the univariate analysis, the multivariate analysis demonstrated that high-risk disease status (P o 0.001) and haploidentical HSCT (P = 0.019) were significantly correlated with a higher incidence of overall mortality post HSCT; in addition, high-risk disease status (P = 0.008) and haploidentical HSCT (Po 0.0001) were correlated with a higher incidence of TRM. In Abbreviations: BM = bone marrow; Bu = busulfan; MDS = myelodysplastic syndrome; NA = not analyzed; NR = nonremission; PB = peripheral blood; RAEB = refractory anemia with excess blast; RC = refractory cytopenia.
addition, a diagnosis of ALL (P = 0.008) and high-risk disease status (P o 0.001) correlated with a higher incidence of RRM (Table 3) . Furthermore, a high-risk of disease status was the only risk factor that correlated with a higher risk of overall mortality (P o 0.0001) in patients receiving haploidentical HSCT. Moreover, a diagnosis of MDS and high-risk disease status correlated with a higher incidence of TRM (P = 0.048 and P = 0.042) in patients receiving haploidentical HSCT. High-risk disease status was the only risk factor correlated with a higher incidence of RRM (Po 0.0001; Table 3 ).
DISCUSSION
This study mainly investigated the incidence, causes and factors influencing mortality after haploidentical HSCT and compared the differences between HLA-identical sibling HSCT and haploidentical HSCT. Our study suggested that compared with HLA-identical sibling HSCT, haploidentical HSCT led to a higher incidence of TRM (27.5% vs 19.9%, P = 0.002) and overall mortality (38.7% vs 33.3%, P = 0.012); in addition, the multivariate analysis also suggested that haploidentical HSCT was a risk factor for TRM and overall mortality (Po0.0001 and P = 0.019). This relationship was probably because of the incidence of infection-related mortality that was higher after haploidentical HSCT than after HLA-identical sibling HSCT (21.2% vs 13.4%, P = 0.002). Our study also suggested that infection was the most common cause of mortality after haploidentical HSCT (49.5%) but the second most common cause of mortality after HLA-identical sibling HSCT (39.2%). Our previous studies suggested that compared with HLA-identical sibling HSCT, haploidentical HSCT increased the incidence of invasive fungal disease (7.1% vs 3.3%, P = 0.007), post transplant lymphoproliferative disease (2.3% vs 0.4%, Po0.05) and CMV disease (8.7% vs 0.0%, P = 0.004) [15] [16] [17] that are usually associated with a higher risk of mortality after transplant. [16] [17] [18] [19] Moreover, our previous study found that the T-cell subset and dendritic cell subgroup counts, especially CD8 + , CD4
+ and CD4 + naive T cells, within the first 90 days post transplant were significantly lower in patients receiving haploidentical HSCT than in HLA-identical sibling HSCT (Po0.05). 20 As a result, the early delayed immune reconstitution after haploidentical HSCT probably led to an increased incidence of infection and infection-related mortality post transplant and finally led to a higher incidence of TRM. Therefore, the regular and intensive monitoring of pathogens after transplant was necessary for patients receiving haploidentical HSCT. In addition to a life-threatening infection, the development of severe GvHD post transplant also correlated with TRM. However, our present study suggested that the incidence of GvHD-related mortality in haploidentical HSCT was comparable to that of HLA-identical sibling Causes of mortality after haploidentical HSCT C-H Yan et al HSCT (3.3% vs 3.0%, P = 0.469), and our previous study also suggested that the incidences of grade 2-4 acute GvHD (40% vs 32%, P = 0.13), grade 3-4 acute GvHD (6.8% vs 4.5%, P = 0.066) and chronic GvHD (55% vs 56%, P = 0.90) were comparable between haploidentical HSCT patients and HLA-identical sibling HSCT patients. 4, 21 These phenomena were probably because of the application of ATG in the conditioning regimen [4] [5] [6] 10 as well as the combined infusion of G-CSF-mobilized PBSCs and BM cells. [22] [23] [24] [25] [26] [27] Many studies have already suggested that the application of G-CSF in vivo can induce immune tolerance by downregulating the expression of CD28/CD80/CD86 costimulatory signals, inhibiting the generation of T helper type 17 cells and promoting regulatory T cell and tolerogenic dendritic cell differentiation. [22] [23] [24] [25] [26] [27] Moreover, GvHD and infection usually are concurrent or occur successively. Therefore, separating GvHD from infection is difficult. Some articles have already suggested that the development of acute GvHD is a risk factor for opportunistic infection, such as invasive fungal disease and CMV reactivation. 15, 19, 28 Our previous study also suggested that although the incidence of grade 2-4 acute GvHD was similar between haploidentical HSCT and HLA-identical sibling HSCT, the incidence of grade 1-4 acute GvHD was significantly higher after haploidentical HSCT than after HLA-identical sibling HSCT (Po0.0001) that increased the use of immunosuppressive agents after haploidentical HSCT compared with HLA-identical sibling HCST; this course finally led to an increased incidence of infection. 21 Therefore, the cause of mortality for patients who had both GvHD and infection was classified according to the main and direct causes of mortality in this study. Relapse remained the major cause of post transplant mortality (32.2% in haploidentical HSCT and 41.5% in HLA-identical sibling HSCT). Our study also suggested that the incidence of RRM of haploidentical HSCT was comparable to that of HLA-identical sibling HSCT (15.6% vs 16.7%, P = 0.943). A multivariate analysis also suggested that haploidentical HSCT did not correlate with RRM, but a diagnosis of ALL and high-risk disease status were significantly correlated with RRM (Po 0.05). Moreover, in patients receiving haploidentical HSCT, high-risk disease status was the only risk factor for RRM (Po 0.0001). These phenomena suggested that haploidentical HSCT may exert a stronger GvL effect than HLA-identical sibling HSCT; therefore, it may overcome the higher relapse risk of ALL in HLA-identical sibling HSCT. Our previous study also suggested that in patients with refractory/relapsed acute leukemia, haploidentical HSCT was associated with a lower relapse rate (26% vs 49%, P = 0.008) and better overall survival (42% vs 20%, P = 0.048) than HLA-identical sibling HSCT. 29 Kanda et al. 30 reported that for standard-risk acute leukemia, the incidence of relapse after HLA-identical sibling HSCT did not significantly differ from that after haploidentical HSCT (22% vs 15%; P = 0.25); in contrast, for high-risk acute leukemia, the incidence of relapse was 47% after HLA-identical sibling HSCT versus 19% after haploidentical HSCT (P = 0.004). However, the underlying biological mechanism needs to be explored further.
In patients with acute leukemia, the incidence of TRM, RRM or overall mortality did not significantly differ between haploidentical HSCT and HLA-identical sibling HSCT (P40.05). The same results were found in our previous article. 4 However, the incidences of TRM and overall mortality in patients with MDS were higher after haploidentical HSCT than after HLA-identical sibling HSCT (P o0.05). Our unpublished data also suggest that the incidence of TRM in the patients with MDS tends to be higher after haploidentical HSCT than after HLA-identical HSCT (31% vs 21%, P = 0.07) (unpublished data). Furthermore, a diagnosis of MDS in patients receiving haploidentical HSCT was correlated with a higher incidence of TRM in our study (P = 0.048). The difference between the patients with acute leukemia and the patients with MDS was probably because of the longer disease duration before transplant in the patients with MDS that was usually associated with a longer duration of neutropenia and frequent blood transfusion that resulted in a higher incidence of TRM. [31] [32] [33] However, the mechanisms underlying the differences between the patients with MDS and the patients with acute leukemia need to be investigated in the future.
This study was also subject to some limitations. The principle limitation was the diversity of the patient populations, particularly when attempting to compare the mortality post transplant between haploidentical HSCT and HLA-identical sibling HSCT. For example, the application of ATG during the conditioning regimen and intensive GvHD prophylaxis probably resulted in stronger immunosuppression in patients receiving haploidentical HSCT than in patients receiving HLA-identical sibling HSCT, probably influencing the development of post-transplant complications, such as infection. However, the application of ATG and intensive GvHD prophylaxis is necessary to overcome the HLA barrier in order to reduce the development of severe GvHD and graft failure after haploidentical HSCT.
This study investigated the incidence, causes and factors influencing mortality after haploidentical HSCT; furthermore, it compared the differences between haploidentical HSCT and HLAidentical sibling HSCT. Our study suggested that haploidentical HSCT led to a higher incidence of TRM and a similar incidence of RRM compared with HLA-identical sibling HSCT that led to a higher incidence of overall mortality than HLA-identical HSCT, especially in patients with MDS. Therefore, HLA-identical sibling HSCT remained the first choice of treatment for the patients with hematological malignancies, especially for patients with MDS, but haploidentical HSCT is available for the patients without HLAidentical sibling donors.
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